Open access
Zanubrutinib monotherapy in CD79B‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study
Li Wang
K. Zhou
Fei Li
Qing-Yuan Zhang
Hui Zhou
O. Bai
Li-Ping Su
Chun-Hong Hu
Zhi-Ming Li
Kai-Yang Ding
Qun-Yi Guo
Xiao-Ling Li
Xiao-Xi Zhou
Wen-Juan Yu
Shu-Hua Yi
Zhi-Xia Wei
Wen-Bin Qian
Fei-Heng Chen
Guo-Hui Cui
Zhi-Yu Liang
Qing-Chao Zeng
J. Lyu
Yang Liu
Pan Zhang
Zhi-Rong Shen
Zai-Xing Shi
Jing Rong
Wei-Li Zhao
Abstract
Diffuse large B ‐ cell lymphoma (DLBCL) remains a clinically and molecularly heterogeneous disease, 1 with approximately one ‐ third of patients developing relapsed or refractory (R/R) disease following frontline immunochemotherapy. 2,3 Among molecularly defined sub-groups, CD79B mutations occur in 5% – 25% of DLBCL